DIFLUOROMETHYLORNITHINE FOR ARSENO-RESISTANT TRYPANOSOMA BRUCEI GAMBIENSE SLEEPING SICKNESS
- 1 December 1987
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 330 (8573), 1431-1433
- https://doi.org/10.1016/s0140-6736(87)91131-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Difluoromethylornithine, an effective new treatment of gambian trypanosomiasisAmerican Journal Of Medicine, 1987
- Clinical and Pathological Aspects of Human African Trypanosomiasis (T. B. Gambiense) with Particular Reference to Reactive Arsenical EncephalopathyThe American Journal of Tropical Medicine and Hygiene, 1986
- The trypanosomiases.BMJ, 1985
- DIAGNOSIS OF AFRICAN AND AMERICAN TRYPANOSOMIASESBritish Medical Bulletin, 1985
- Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-α-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trialTransactions of the Royal Society of Tropical Medicine and Hygiene, 1985
- New Drug Combination for Experimental Late-Stage African Trypanosomiasis: DL-α-Difluoromethylornithine (DFMO) with SuraminThe American Journal of Tropical Medicine and Hygiene, 1984
- Chemotherapeutic implications of polyamine biosynthesis inhibitionClinical Pharmacology & Therapeutics, 1984
- Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylaseClinical Pharmacology & Therapeutics, 1981
- Polyamine Metabolism: A Potential Therapeutic Target in TrypanosomesScience, 1980
- The pathogenesis of sleeping sicknessTransactions of the Royal Society of Tropical Medicine and Hygiene, 1980